February 28, 2023
DeciBio conducted 10 interviews with academic researchers and biopharma executives to explore how advanced and next-generation proteomics tools have been adopted into research efforts today
DeciBio conducted 10 interviews with academic researchers and biopharma executives to explore how advanced and next-generation proteomics tools (e.g. high plex, high sensitivity, hypothesis-free) have been adopted into research efforts today. Many of these tools enable applications that far surpass the capabilities of ELISA and blotting methods, and stakeholders were asked to comment on the key use cases pursued with these newer technologies, rank top assay selection criteria, and provide feedback on assay providers / test vendors. The technologies discussed span many technical classes, (antibody, aptamer, protein sequencing) collectively called 'Next Generation Proteomics' (NGP), and this report provides a qualitative summary of these interviews. In response to each key interview question, DeciBio provides several condensed takeaways and a curated list of quotes indicative of stakeholder feedback.
This advisory board is meant to be a qualitative, limited scope study, and the intent is to highlight the unbiased and unfiltered feedback just from the stakeholders interviewed, not provide a comprehensive market assessment. DeciBio also has a suite of comprehensive market reports (Link Here) if broader industry level insights are of interest.